Company intelligence / Profile preview
Rinri Therapeutics
- Ownership
- Private
- Employees
- ~30
- Development stage
- Preclinical
Overview
Rinri Therapeutics has developed a proprietary regenerative cell therapy platform targeting sensorineural hearing loss by replacing lost or damaged auditory neurons. Their lead candidate, Rincell‑1, demonstrated reversal of hearing loss and ~40% improvement in hearing threshold in preclinical models. The company has regulatory validation to begin first-in-human trials in the UK during 2025. Additional pipeline programs target alternative neuronal replacement strategies and hair cell regeneration.
- Therapeutic areas
- Neurology
- Modalities
- Regenerative cell therapy (stem cell-derived auditory neuron precursors)Pluripotent stem cells reprogrammed into auditory sensory cells
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Rinri Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rinri Therapeutics.